Behçet’s disease (BD) is a multisystemic disorder of unknown etiology mainly defined by recurrent oral aphthosis, genital ulcers, and chronic relapsing bilateral uveitis, all of which represent the “stigmata” of disease. However, many other organs including the vascular, neurological, musculoskeletal, and gastrointestinal systems can be affected. The gastrointestinal involvement in Behçet’s disease (GIBD), along with the neurological and vascular ones, represents the most feared clinical manifestation of BD, and shares many symptoms with inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis. Consequently, the differential diagnosis is often a daunting task, albeit the presence of typical endoscopic and pathologic findings may be a valuable aid to the exact diagnosis. To date, there are no standardized medical treatments for GIBD, therefore therapy should be tailored to the single patient and based on the severity of the clinical features and their complications. This work provides a digest of all current experience and evidence about pharmacological agents suggested by the medical literature as having a potential role for managing the dreadful features of GIBD.

Lopalco, G., Rigante, D., Venerito, V., Fabiani, C., Franceschini, R., Barone, M., Lapadula, G., Galeazzi, M., Frediani, B., Iannone, F., Cantarini, L., Update on the medical management of gastrointestinal Behçet’s disease., <<MEDIATORS OF INFLAMMATION>>, 2017; 2017 (1460491): 1-10. [doi:10.1155/2017/1460491] [http://hdl.handle.net/10807/92006]

Update on the medical management of gastrointestinal Behçet’s disease.

Rigante, Donato
Secondo
;
2017

Abstract

Behçet’s disease (BD) is a multisystemic disorder of unknown etiology mainly defined by recurrent oral aphthosis, genital ulcers, and chronic relapsing bilateral uveitis, all of which represent the “stigmata” of disease. However, many other organs including the vascular, neurological, musculoskeletal, and gastrointestinal systems can be affected. The gastrointestinal involvement in Behçet’s disease (GIBD), along with the neurological and vascular ones, represents the most feared clinical manifestation of BD, and shares many symptoms with inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis. Consequently, the differential diagnosis is often a daunting task, albeit the presence of typical endoscopic and pathologic findings may be a valuable aid to the exact diagnosis. To date, there are no standardized medical treatments for GIBD, therefore therapy should be tailored to the single patient and based on the severity of the clinical features and their complications. This work provides a digest of all current experience and evidence about pharmacological agents suggested by the medical literature as having a potential role for managing the dreadful features of GIBD.
2017
Inglese
Lopalco, G., Rigante, D., Venerito, V., Fabiani, C., Franceschini, R., Barone, M., Lapadula, G., Galeazzi, M., Frediani, B., Iannone, F., Cantarini, L., Update on the medical management of gastrointestinal Behçet’s disease., <<MEDIATORS OF INFLAMMATION>>, 2017; 2017 (1460491): 1-10. [doi:10.1155/2017/1460491] [http://hdl.handle.net/10807/92006]
File in questo prodotto:
File Dimensione Formato  
Lopalco et al.pdf

accesso aperto

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.29 MB
Formato Adobe PDF
1.29 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/92006
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 12
social impact